nach oben

Die Dermatologie

Erschienen in:

06.07.2021 | Wundbehandlung | Leitthema

Hidradenitis suppurativa/Acne inversa – operative Optionen, Rekonstruktionen und Kombinationen mit medikamentösen Therapien – Ein Update

verfasst von: P. Cramer, S. Schneider-Burrus, M. Kovács, L. Scholl, M. Podda, Prof. Dr. F. G. Bechara

Erschienen in: Die Dermatologie | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hidradenitis suppurativa/Acne inversa (HS/AI) ist eine chronisch-entzündliche Hauterkrankung, deren Behandlung sowohl konservative als auch chirurgische Behandlungsmöglichkeiten umfasst. In den Hurley-Stadien II und III ist die chirurgische Resektion irreversibel zerstörten Gewebes anzustreben. Hierzu existieren verschiedene Resektionstechniken, die sich vor allem in ihrer Invasivität und Rezidivneigung unterscheiden. Bis heute gibt es keinen allgemein akzeptierten Konsens hinsichtlich verschiedener Resektions- und Rekonstruktionstechniken sowie der Einbeziehung medikamentöser Therapien in das therapeutische Gesamtkonzept.

Kirschke J, Hessam S, Bechara FG (2015) Hidradenitis suppurativa/acne inversa: Ein Update. Hautarzt 66:413–422. https://doi.org/10.1007/s00105-015-3616-yCrossRefPubMed

Sabat R (2017) Acne inversa/hidradenitis suppurativa: a challenge for the future. Hautarzt 68:994–998. https://doi.org/10.1007/s00105-017-4079-0CrossRefPubMed

Sabat R, Tsaousi A, Rossbacher J et al (2017) Acne inversa/hidradenitis suppurativa: an update. Hautarzt 68:999–1006. https://doi.org/10.1007/s00105-017-4082-5CrossRefPubMed

Patel ZS, Hoffman LK, Buse DC, Grinberg AS, Afifi L, Cohen SR et al (2017) Pain, psychological comorbidities, disability, and impaired quality of life in hidradenitis suppurativa. Curr Pain Headache Rep 21(12):49PubMedPubMedCentralCrossRef

McPhie ML, Bridgman AC, Kirchhof MG (2019) Combination therapies for hidradenitis suppurativa: a retrospective chart review of 31 patients. J Cutan Med Surg 23(3):270–276PubMedCrossRef

Hurley H (1989) Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus. Surgical approach. In: Roenigk RK, Roenigk HH Jr (Hrsg) Dermatologic surgery. Principles and practice. Dekker, New York, S 729–739

Bechara FG (2016) MIBHS: a concept to distinguish between medical and surgical treatment in hidradenitis suppurativa. Exp Dermatol 25(Suppl):8. https://doi.org/10.1111/exd.12954CrossRef

Bechara FG, Hessam S (2016) Hidradenitis suppurativa. MMW Fortschr Med 158:52–53. https://doi.org/10.1007/s15006-016-8662-6CrossRefPubMed

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C et al (2019) North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol 81(1):76–90PubMedCrossRef

10.

Zouboulis CC, Bechara FG, Fritz K et al (2012) S1-Leitlinie zur Therapie der Hidradenitis suppurativa/Acne inversa. J Dtsch Dermatol Ges 10(Suppl 5):S1–S31. https://doi.org/10.1111/j.1610-0387.2012.08006.xCrossRefPubMed

11.

Zouboulis CC, Desai N, Emtestam L et al (2015) European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 29:619–644. https://doi.org/10.1111/jdv.12966CrossRefPubMed

12.

Banerjee AK (1992) Surgical treatment of hidradenitis suppurativa. Br J Surg 79:863–866PubMedCrossRef

13.

Jemec GBE (2012) Clinical practice. Hidradenitis suppurativa. N Engl J Med 366:158–164. https://doi.org/10.1056/NEJMcp1014163CrossRefPubMed

14.

Zouboulis CC, Bechara FG, Dickinson-Blok JL, Gulliver W, Horváth B, Hughes R et al (2019) Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization—Systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol 33(1):19–31PubMedCrossRef

15.

van der Zee HH, Prens EP, Boer J (2010) Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol 63:475–480. https://doi.org/10.1016/j.jaad.2009.12.018CrossRefPubMed

16.

Dahmen RA, Gkalpakiotis S, Mardesicova L, Arenberger P, Arenbergerova M (2019) Deroofing followed by thorough sinus tract excision: a modified surgical approach for hidradenitis suppurativa. J Dtsch Dermatol Ges 17(7):698–702PubMed

17.

Aksakal AB, Adişen E (2008) Hidradenitis suppurativa: importance of early treatment; efficient treatment with electrosurgery. Dermatol Surg 34:228–231. https://doi.org/10.1111/j.1524-4725.2007.34042.xCrossRefPubMed

18.

van Hattem S, Spoo JR, Horváth B et al (2012) Surgical treatment of sinuses by deroofing in hidradenitis suppurativa. Dermatol Surg 38:494–497. https://doi.org/10.1111/j.1524-4725.2011.02255.xCrossRefPubMed

19.

Hazen PG, Hazen BP (2010) Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg 36:208–213. https://doi.org/10.1111/j.1524-4725.2009.01427.xCrossRefPubMed

20.

Janse IC, Hellinga J, Blok JL et al (2016) Skin-tissue-sparing excision with electrosurgical peeling: a case series in hidradenitis suppurativa. Acta Derm Venereol 96:390–391. https://doi.org/10.2340/00015555-2258CrossRefPubMed

21.

Blok JL, Spoo JR, Leeman FWJ et al (2015) Skin-Tissue-sparing Excision with Electrosurgical Peeling (STEEP): a surgical treatment option for severe hidradenitis suppurativa Hurley stage II/III. J Eur Acad Dermatol Venereol 29:379–382. https://doi.org/10.1111/jdv.12376CrossRefPubMed

22.

Endo Y, Tamura A, Ishikawa O, Miyachi Y (1998) Perianal hidradenitis suppurativa: early surgical treatment gives good results in chronic or recurrent cases. Br J Dermatol 139:906–910PubMedCrossRef

23.

Greeley PW (1951) Plastic surgical treatment of chronic suppurative hidradenitis. Plast Reconstr Surg 7:143–146CrossRef

24.

Mandal A, Watson J (2005) Experience with different treatment modules in hidradenitis suppuritiva: a study of 106 cases. Surgeon 3:23–26PubMedCrossRef

25.

Ingram JR, Collier F, Brown D, Burton T, Burton J, Chin MF et al (2019) British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol 180(5):1009–1017PubMedCrossRef

26.

Bilali S, Todi V, Lila A et al (2012) Surgical treatment of chronic hidradenitis suppurativa in the gluteal and perianal regions. Acta Chir Iugosl 59:91–95PubMedCrossRef

27.

Broadwater JR, Bryant RL, Petrino RA et al (1982) Advanced hidradenitis suppurativa. Review of surgical treatment in 23 patients. Am J Surg 144:668–670PubMedCrossRef

28.

Fernandes NC, Franco CPA, Lima CMO (2013) Hidradenitis suppurativa: retrospective study of 20 cases. An Bras Dermatol 88:480–481. https://doi.org/10.1590/abd1806-4841.20131637CrossRefPubMedPubMedCentral

29.

Martorell A, Giovanardi G, Gomez-Palencia P, Sanz-Motilva V (2019) Defining fistular patterns in hidradenitis suppurativa. Dermatol Surg 45(10):1237–1244PubMedCrossRef

30.

Humphries LS, Kueberuwa E, Beederman M, Gottlieb LJ (2016) Wide excision and healing by secondary intent for the surgical treatment of hidradenitis suppurativa: a single-center experience. J Plast Reconstr Aesthet Surg 69:554–566. https://doi.org/10.1016/j.bjps.2015.12.004CrossRefPubMed

31.

Parks RW, Parks TG, Hughes LE (1997) Pathogenesis, clinical features and management of hidradenitis suppurativa. Ann R Coll Surg Engl 79:309–310

32.

Rompel R, Petres J (2000) Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg 26:638–643PubMedCrossRef

33.

Takiyama H, Kazama S, Tanoue Y et al (2015) Efficacy of magnetic resonance imaging in the diagnosis of perianal hidradenitis suppurativa, complicated by anal fistulae: a report of two cases and review of the literature. Int J Surg Case Rep 15:107–111. https://doi.org/10.1016/j.ijscr.2015.08.028CrossRefPubMedPubMedCentral

34.

Scholl L, Hessam S, Reitenbach S, Bechara FG (2018) Operative Behandlungsoptionen bei Hidradenitis suppurativa/Acne inversa. Hautarzt 69:149–161. https://doi.org/10.1007/s00105-017-4114-1CrossRefPubMed

35.

Ariyan S, Krizek TJ (1976) Hidradenitis suppurativa of the groin, treated by excision and spontaneous healing. Plast Reconstr Surg 58:44–47PubMedCrossRef

36.

Ather S, Chan DSY, Leaper DJ, Harding KG (2006) Surgical treatment of hidradenitis suppurativa: case series and review of the literature. Int Wound J 3:159–169. https://doi.org/10.1111/j.1742-481X.2006.00235.xCrossRefPubMedPubMedCentral

37.

Balik E, Eren T, Bulut T et al (2009) Surgical approach to extensive hidradenitis suppurativa in the perineal/perianal and gluteal regions. World J Surg 33:481–487. https://doi.org/10.1007/s00268-008-9845-9CrossRefPubMed

38.

Kagan RJ, Yakuboff KP, Warner P, Warden GD (2019) Surgical treatment of hidradenitis suppurativa: a 10-year experience. Surgery 138(4):734–741CrossRef

39.

Bieniek A, Matusiak L, Okulewicz-Gojlik D, Szepietowski JC (2010) Surgical treatment of hidradenitis suppurativa: experiences and recommendations. Dermatol Surg 36:1998–2004. https://doi.org/10.1111/j.1524-4725.2010.01763.xCrossRefPubMed

40.

Harrison BJ, Mudge M, Hughes LE (1987) Recurrence after surgical treatment of hidradenitis suppurativa. Br Med J 294:487–489CrossRef

41.

Bocchini SF, Habr-Gama A, Kiss DR et al (2003) Gluteal and perianal hidradenitis suppurativa: surgical treatment by wide excision. Dis Colon Rectum 46:944–949. https://doi.org/10.1097/01.DCR.0000070046.16402.DFCrossRefPubMed

42.

Wollina U, Tilp M, Meseg A et al (2012) Management of severe anogenital acne inversa (hidradenitis suppurativa). Dermatol Surg 38:110–117. https://doi.org/10.1111/j.1524-4725.2011.02157.xCrossRefPubMed

43.

van Rappard DC, Mooij JE, Mekkes JR (2012) Mild to moderate hidradenitis suppurativa treated with local excision and primary closure. J Eur Acad Dermatol Venereol 26:898–902. https://doi.org/10.1111/j.1468-3083.2011.04203.xCrossRefPubMed

44.

Grösser A (1982) Surgical treatment of chronic axillary and genitocrural acne conglobata by splitthickness skin grafting. J Dermatol Surg Oncol 8:391–398. https://doi.org/10.1111/j.1524-4725.1982.tb00303.xCrossRefPubMed

45.

Mustafa EB, Ali SD, Kurtz LH (1980) Hidradenitis suppurativa: review of the literature and management of the axillary lesion. J Natl Med Assoc 72:237–243PubMedPubMedCentral

46.

Watson JD (1985) Hidradenitis suppurativa–A clinical review. Br J Plast Surg 38:567–569. https://doi.org/10.1016/0007-1226(85)90022-0CrossRefPubMed

47.

Anderson BB, Cadogan CA, Gangadharam D (1982) Hidradenitis suppurativa of the perineum, scrotum, and gluteal area: presentation, complications, and treatment. J Natl Med Assoc 74:999–1003PubMedPubMedCentral

48.

Chapman J (1972) The surgical treatment of hidradenitis suppurativa. J Natl Med Assoc 64:328–330PubMedPubMedCentral

49.

Grimstad Ø, Tzellos T, Dufour DN, Bremnes Ø, Skoie IM, Snekvik I et al (2019) Evaluation of medical and surgical treatments for hidradenitis suppurativa using real-life data from the Scandinavian registry (HISREG). J Eur Acad Dermatol Venereol 33(6):1164–1171PubMedCrossRef

50.

Kuo H, Ohara K (2003) Surgical treatment of chronic gluteal hidradenitis suppurativa: reused skin graft technique. Dermatol Surg 29:173–178. https://doi.org/10.1046/j.1524-4725.2003.29044.xCrossRefPubMed

51.

Gonzaga TA, Endorf FW, Mohr WJ, Ahrenholz DH (2013) Novel surgical approach for axillary hidradenitis suppurativa using a bilayer dermal regeneration template: a retrospective case study. J Burn Care Res 34:51–57. https://doi.org/10.1097/BCR.0b013e31826a7be7CrossRefPubMed

52.

Rockwell WB, Yamashita Y, Hashimoto I et al (2014) Commentary: two-stage surgery for hidradenitis suppurativa: staged artificial dermis and skin grafting. Dermatol Surg 40:116–117. https://doi.org/10.1111/dsu.12435CrossRefPubMed

53.

Melkun ET, Few JW (2005) The use of biosynthetic skin substitute (Biobrane) for axillary reconstruction after surgical excision for hidradenitis suppurativa. Plast Reconstr Surg 115:1385–1388. https://doi.org/10.1097/01.PRS.0000157013.40191.91CrossRefPubMed

54.

Morykwas MJ, Argenta LC, Shelton-Brown EI, McGuirt W (1997) Vacuum-assisted closure: a new method for wound control and treatment: animal studies and basic foundation. Ann Plast Surg 38:553–562PubMedCrossRef

55.

Büyükaşik O, Hasdemir AO, Kahramansoy N et al (2011) Surgical approach to extensive hidradenitis suppurativa. Dermatol Surg 37:835–842. https://doi.org/10.1111/j.1524-4725.2011.01961.xCrossRefPubMed

56.

Civelek B, Aksoy K, Bilgen E et al (2010) Reconstructive options in severe cases of Hidradenitis suppurativa. Open Med. https://doi.org/10.2478/s11536-009-0126-2CrossRef

57.

Rehman N, Kannan RY, Hassan S, Hart NB (2005) Thoracodorsal artery perforator (TAP) type I V‑Y advancement flap in axillary hidradenitis suppurativa. Br J Plast Surg 58:441–444. https://doi.org/10.1016/j.bjps.2004.10.022CrossRefPubMed

58.

Altmann S, Fansa H, Schneider W (2001) Surgical treatment of axillary hidradenitis suppurativa. Chirurg 72:1413–1416PubMedCrossRef

59.

Rieger UM, Erba P, Pierer G, Kalbermatten DF (2009) Hidradenitis suppurativa of the groin treated by radical excision and defect closure by medial thigh lift: aesthetic surgery meets reconstructive surgery. J Plast Reconstr Aesthet Surg 62:1355–1360. https://doi.org/10.1016/j.bjps.2008.04.035CrossRefPubMed

60.

Soldin MG, Tulley P, Kaplan H et al (2000) Chronic axillary hidradenitis–the efficacy of wide excision and flap coverage. Br J Plast Surg 53:434–436. https://doi.org/10.1054/bjps.1999.3285CrossRefPubMed

61.

Janse I, Bieniek A, Horváth B, Matusiak L (2016) Surgical procedures in hidradenitis suppurativa. Dermatol Clin 34:97–109. https://doi.org/10.1016/j.det.2015.08.007CrossRefPubMed

62.

Wiltz O, Schoetz DJ, Murray JJ et al (1990) Perianal hidradenitis suppurativa. The Lahey clinic experience. Dis Colon Rectum 33:731–734PubMedCrossRef

63.

Morgan WP, Harding KG, Hughes LE (1983) A comparison of skin grafting and healing by granulation, following axillary excision for hidradenitis suppurativa. Ann R Coll Surg Engl 65:235–236PubMedPubMedCentral

64.

Wollina U, Langner D, Heinig B, Nowak A (2017) Comorbidities, treatment, and outcome in severe anogenital inverse acne (hidradenitis suppurativa): a 15-year single center report. Int J Dermatol 56:109–115. https://doi.org/10.1111/ijd.13393CrossRefPubMed

65.

Kagan RJ, Yakuboff KP, Warner P, Warden GD (2005) Surgical treatment of hidradenitis suppurativa: a 10-year experience. Surgery 138:734–740. https://doi.org/10.1016/j.surg.2005.06.053 ((discussion 740–741))CrossRefPubMed

66.

Bettoli V, Manfredini M, Massoli L, Carillo C, Barozzi A, Amendolagine G et al (2019) Rates of antibiotic resistance/sensitivity in bacterial cultures of hidradenitis suppurativa patients. J Eur Acad Dermatol Venereol 33(5):930–936PubMedCrossRef

67.

Schneller-Pavelescu L, Vergara-de Caso E, Martorell A, Romaní J, Lázaro M, Vilarrasa E et al (2019) Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: an observational study to assess prevalence and causes. J Am Acad Dermatol 80(5):1455–1457PubMedCrossRef

68.

Albrecht J, Baine PA, Ladizinski B, Jemec GB, Bigby M (2019) Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa: a critically appraised topic. Br J Dermatol 180(4):749–755PubMedCrossRef

69.

Marasca C, Masarà A, Annunziata MC, Bettoli V, Luciano MA, Fabbrocini G (2019) Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa: strategy to reduce side effects, improving patients’ compliance. Br J Dermatol 180(4):949PubMedCrossRef

70.

Delage M, Jais JP, Lam T, Guet-Revillet H, Ungeheuer MN, Consigny PH et al (2020) Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley stage 1 hidradenitis suppurativa: prospective short-term trial and one-year follow-up in 28 consecutive patients. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2020.01.007CrossRef

71.

Andersen RK, Jemec GB (2017) Treatments for hidradenitis suppurativa. Clin Dermatol 35:218–224. https://doi.org/10.1016/j.clindermatol.2016.10.018CrossRefPubMed

72.

Falola RA, DeFazio MV, Anghel EL et al (2016) What heals hidradenitis suppurativa: surgery, immunosuppression, or both? Plast Reconstr Surg 138:219S–229S. https://doi.org/10.1097/PRS.0000000000002671CrossRefPubMed

73.

Van Rappard DC, Mekkes JR (2012) Treatment of severe hidradenitis suppurativa with infliximab in combination with surgical interventions. Br J Dermatol 167:206–208. https://doi.org/10.1111/j.1365-2133.2012.10807.xCrossRefPubMed

74.

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C et al (2019) North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol 81(1):91–101PubMedCrossRef

75.

Argyropoulou M, Kanni T, Kyprianou M, Melachroinopoulos N, Giamarellos-Bourboulis EJ (2019) Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort. Br J Dermatol 180(5):1161–1168PubMedCrossRef

76.

Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C et al (2019) Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3‑year results of a phase 3 open-label extension study. J Am Acad Dermatol 80(1):60–69.e2PubMedCrossRef

77.

Jemec GB, Okun MM, Forman SB, Gulliver WP, Prens EP, Mrowietz U et al (2019) Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase 3, randomized, placebo-controlled, PIONEER trials. Br J Dermatol 181(5):967–975PubMedPubMedCentralCrossRef

78.

Oskardmay AN, Miles JA, Sayed CJ (2019) Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa. J Am Acad Dermatol 81(3):702–708PubMedCrossRef

79.

Vossen AR, van Doorn MB, van der Zee HH, Prens EP (2019) Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial. J Am Acad Dermatol 80(1):80–88PubMedCrossRef

80.

Kerdel FR, Azevedo FA, Kerdel Don C, Don FA, Fabbrocini G, Kerdel FA (2019) Apremilast for the treatment of mild-to-moderate hidradenitis suppurativa in a prospective, open-label, phase 2 study. J Drugs Dermatol 18(2):170–176PubMed

81.

André R, Marescassier H, Gabay C, Pittet B, Laffitte E (2019) Long-term therapy with anakinra in hidradenitis suppurativa in three patients. Int J Dermatol 58(11):e208–e209PubMedCrossRef

82.

Prussick L, Rothstein B, Joshipura D, Saraiya A, Turkowski Y, Abdat R et al (2019) Open-label, investigator-initiated, singlesite exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol 181(3):609–611PubMedCrossRef

83.

Casseres RG, Kahn JS, Her MJ, Rosmarin D (2019) Guselkumab in the treatment of hidradenitis suppurativa: a retrospective chart review. J Am Acad Dermatol 81(1):265–267PubMedCrossRef

84.

Scheinfeld N (2013) Hidradenitis suppurativa: a practical review of possible medical treatments based on over 350 hidradenitis patients. Dermatol Online J 19(4):1PubMedCrossRef

85.

Provini LE, Stellar JJ, Stetzer MN, Nguyen PD, Jen M (2019) Combination hyperbaric oxygen therapy and ustekinumab for severe hidradenitis suppurativa. Pediatr Dermatol 36(3):381–383PubMedCrossRef

86.

Kovacs M, Podda M (2019) Guselkumab in the treatment of severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol 33(3):e140–e141PubMedCrossRef

87.

Casseres RG, Prussick L, Zacanaro R, Rothstein B, Joshipura D et al (2020) Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open label trial. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2020.02.005CrossRefPubMed

88.

Savage KT, Brant EG, Santillan MR, Morss PC, Salian P et al (2020) Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa. Int J Womens Dermatol. https://doi.org/10.1016/j.ijwd.2020.02.007CrossRefPubMedPubMedCentral

89.

Giamarellos-Bourboulis EJ, Bettoli V, Jemec GBE, del Marmol V, Marzano AV, Prens EP, Tzellos T, Zouboulis CC (2021) Anti-COVID-19 measurements for hidradenitis suppurativa patients. Exp Dermatol 30:18–22PubMedPubMedCentralCrossRef

90.

Kovacs M, Podda M (2021) Current changes in the standard of care of hidradenitis suppurativa patients in a German specialist clinic due to the COVID-19 pandemic. Exp Dermatol 30:82

91.

Podda M, Hasche E, Kovacs M (2021) Tumescence vs. general anesthesia: a precious alternative in large hidradenitis suppurativa surgery learned due to the COVID-19 pandemic. Exp Dermatol 30:70–71

Titel: Hidradenitis suppurativa/Acne inversa – operative Optionen, Rekonstruktionen und Kombinationen mit medikamentösen Therapien – Ein Update
verfasst von: P. Cramer
S. Schneider-Burrus
M. Kovács
L. Scholl
M. Podda
Prof. Dr. F. G. Bechara
Publikationsdatum: 06.07.2021
Verlag: Springer Medizin
Schlagwörter: Wundbehandlung
Acne inversa
Lappenplastik
Lappenplastik
Erschienen in: Die Dermatologie / Ausgabe 8/2021
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI: https://doi.org/10.1007/s00105-021-04864-8

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Beispielhafte Darstellung der Deroofing-Technik bei einem oberflächlichen Sinustrakt/© Springer Medizin Verlag GmbH, Die Leitlinien für Ärztinnen und Ärzte, Frau bekommt eine Laserbehandlung/© veles_studio / stock.adobe.com (Symbolbild mit Fotomodell), Tote Biene auf dem Boden/© Delphotostock / stock.adobe.com (Symbolbild), Gewöhnliche Skabies an der Hand einer älteren Frau/© Springer Verlag GmbH, Bakterienkultur in Petrischale/© nuengneng / Stock.adobe.com (Symbolbild mit Fotomodell)

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2021

Pathogenese der Hidradenitis suppurativa/Acne inversa

Klinische, pathologische und molekulare Biomarker der Hidradenitis suppurativa/Acne inversa

Bedarf von Real-World-klinischen Therapiestudien für die Hidradenitis suppurativa/Acne inversa

Acne inversa: eine seltene Erkrankung mit weitreichenden Auswirkungen für Betroffene

Entwicklung eines Ivermectin-haltigen Saftes als Magistralrezeptur für Kinder zur Therapie der Skabies